1 unchanged sentence
Rule 10b5-1 Trading Plans
−Removed: During the three months ended March 31, 2024, none of our directors or officers (as defined in Rule-1(f) of the Exchange Act) adopted , modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408 of Regulation S-K.
+Added: During the three months ended June 30, 2024, the following directors and officers (as defined in Rule-1(f) of the Exchange Act) adopted , modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408 of Regulation S-K.
+Added: • Gail Boudreaux , President and Chief Executive Officer and member of our Board of Directors, adopted a stock trading plan on April 19, 2024 , pursuant to which she may sell up to 34,000 shares of our common stock prior to October 31, 2024 .
+Added: • Ramiro Peru , a member of our Board of Directors , adopted a stock trading plan on May 6, 2024 , pursuant to which he may sell up to 753 shares of the Company’s common stock prior to May 6, 2025 .
+Added: • Mark Kaye , Executive Vice President and Chief Financial Officer , adopted a stock trading plan on April 22, 2024 , pursuant to which he may sell up to 6,758 shares of our common stock prior to February 28, 2025 .
+Added: Each of these trading plans was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended, and the Company’s policies regarding transactions in our securities.
3.1 Amended and Restated Articles of Incorporation of the Company, as amended and restated effective June 27, 2022, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 28, 2022.
3.2 Bylaws of the Company, as amended effective October 4, 2023, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on October 5, 2023.
+Added: Form of 5.150% Notes due 2029, incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed on May 30, 2024.
+Added: 375 % Notes due 20 34 , incorporated by reference to Exhibit 4.
+Added: 3 to the Company's Current Report on Form 8-K filed on May 30, 2024.
+Added: Form of 5.650% Notes due 2054, incorporated by reference to Exhibit 4.4 to the Company's Current Report on Form 8-K filed on May 30, 2024.
4.5 Upon the request of the U.S.
Securities and Exchange Commission, the Company will furnish copies of any other instruments defining the rights of holders of long-term debt of the Company or its subsidiaries.
−Removed: 10.2 (p) * Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2024.
−Removed: (q) * Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 2024.
−Removed: Form of Incentive Compensation Plan Performance Stock Unit Award Agreement for 2024.
−Removed: 10.3 Elevance Health Comprehensive Nonqualified Deferred Compensation Plan, as amended and restated effective January 1, 2024, incorporated by reference to Exhibit 10.3 to the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
−Removed: Elevance Health Executive Agreement Plan, as amended and restated effective March 1, 2024.
−Removed: 10.9 (d) * F orm of Employ ment Agreement between t he Company and Ratnakar Lavu, incorporated by reference to Exhibit 10.9 (d) to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30 , 20 23 .
31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act Rules, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
11 unchanged sentences
104 Cover Page Interactive Data File formatted in Inline XBRL and contained in Exhibit 101.
−Removed: * Indicates management contracts or compensatory plans or arrangements.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ELEVANCE HEALTH, INC.
−Removed: April 18, 2024 By:
+Added: July 17, 2024 By:
/ S / M ARK B.
1 unchanged sentence
(Duly Authorized Officer and Principal Financial Officer)
−Removed: April 18, 2024 By:
+Added: July 17, 2024 By:
/ S / R ONALD W.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.